secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revolution Medicines, Inc. (RVMD)
CIK:        0001628171
Form:       8-K
Filed at:   2024-07-15T23:59:59+00:00
Accession:  0001193125-24-178836
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revolution Medicines guides 2024 net loss $560-600M; RMC-6236 shows 8.1-month PFS in 2L PDAC, Phase 3 planned
--------------------------------------------------------------------------------

- Net loss for FY2024 expected $560-600M, including $70-80M non-cash stock-based comp.
- Cash runway into 2027; current cash, equivalents, and marketable securities sufficient.
- RMC-6236 in 2L metastatic PDAC: median PFS 8.1 months (KRAS G12X); ORR 27% (20+ weeks treatment).
- Safety: 96% any-grade TRAEs, 22% Grade ≥3; 0% discontinuation; dose intensity 94%.
- Plans to initiate randomized Phase 3 RASolute 302 in 2H 2024 vs investigator's choice chemo.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628171/000119312524178836/0001193125-24-178836-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628171/000119312524178836/d869775d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-178836

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer